About
Biolojic Design is a biopharmaceutical company dedicated to the development of human antibody-based therapeutics for cancer and other diseases. Biolojic Design has developed a new tool to re-engineer antibodies to bind new epitopes in a process known as re-epitoping. This technology has been shown to yield functional antibodies in difficult targets. Using proprietary algorithms, the company identifies an existing antibody that can be re-epitoped to bind the desired target. The antibody template is then engineered in an iterative computational and experimental approach to bind the desired epitope with high affinity. In 2014, Biolojic partnered with AstraZeneca's MedImmune LLC Biologics unit to discover antibodies for undisclosed targets selected by MedImmune, using Biolojic's computational and biochemical tools.
Funding history · 3 rounds · $4.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Biolojic Design's core focus?
- Biolojic Design is a biopharmaceutical company focused on developing human antibody-based therapeutics for cancer and other diseases.
- When did Biolojic Design partner with AstraZeneca's MedImmune LLC Biologics unit?
- In 2014, Biolojic Design partnered with AstraZeneca's MedImmune LLC Biologics unit to discover antibodies for undisclosed targets using Biolojic's computational and biochemical tools.
- What was Biolojic Design's most recent funding round?
- In March 2025, Biolojic Design secured $7,500,000 in Debt Financing.
- Which investors participated in Biolojic Design's equity crowdfunding round?
- In January 2021, OurCrowd, aMoon Fund, and Winnovation invested in Biolojic Design's equity crowdfunding round, which raised $3,950,200.
- When did Biolojic Design announce a research collaboration with Lilly?
- In March 2021, Biolojic Design announced a research collaboration with Lilly to discover and develop antibody therapies for diabetes.
- What significant development did Biolojic Design achieve in April 2022?
- In April 2022, Biolojic Design's first-ever computationally designed antibody entered human clinical trials in cancer patients.
- When did Biolojic Design appoint Ronald Herbst, Ph.D., as Chief Scientific Officer?
- In September 2022, Biolojic Design appointed Ronald Herbst, Ph.D., as Chief Scientific Officer.
- What collaboration did Biolojic Design announce in June 2024?
- In June 2024, Biolojic Design announced a drug discovery collaboration with Merck, potentially worth up to 346 million euros.
- What was the nature of Biolojic Design's agreement with Teva in December 2023?
- In December 2023, Teva acquired rights for Biolojic Design's asthma treatment.